Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

862
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
862
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation01:30

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation

1.0K
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
1.0K
Irritable Bowel Syndrome I: Introduction01:17

Irritable Bowel Syndrome I: Introduction

1.4K
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
1.4K
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

1.2K
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.2K
Irritable Bowel Syndrome III: Medical and Nursing Management01:30

Irritable Bowel Syndrome III: Medical and Nursing Management

986
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
986
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

931
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
931

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

When Pharmacology Meets Expectancy: Lessons From Two Negative Trials in Disorders of Gut-Brain Interaction.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

Associations Between Physical Activity and Irritable Bowel Syndrome in the All of Us Research Program.

The American journal of gastroenterology·2026
Same author

A Randomized Trial of Rifaximin vs Low Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols Diet for Symptom Outcomes and Microbiome Changes in Irritable Bowel Syndrome.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols Reintroduction in Clinical Practice: Surveying the Gaps and Opportunities.

Gastro hep advances·2026
Same author

Association of Body Mass Index With Disorders of Gut-Brain Interaction: A Large Global Population-Based Analysis.

The American journal of gastroenterology·2026
Same author

Clinical Symptoms Do Not Distinguish Sucrose Malabsorption From SIBO.

Neurogastroenterology and motility·2026

Related Experiment Video

Updated: Mar 28, 2026

Functional Assessment of Intestinal Motility and Gut Wall Inflammation in Rodents: Analyses in a Standardized Model of Intestinal Manipulation
09:44

Functional Assessment of Intestinal Motility and Gut Wall Inflammation in Rodents: Analyses in a Standardized Model of Intestinal Manipulation

Published on: September 11, 2012

23.1K

ORP-101 in Irritable Bowel Syndrome With Diarrhea: A Phase II Randomized, Controlled Trial.

Prashant Singh1, Judy W Nee2, Sarah Ballou2

  • 1Division of Gastroenterology, Department of Medicine, University of Michigan, Ann Arbor, Michigan.

Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|March 26, 2026
PubMed
Summary

A new medication, ORP-101, was tested for irritable bowel syndrome with diarrhea (IBS-D). While not meeting the primary goal, the 100 mg dose showed promise in improving symptoms and was well-tolerated.

Keywords:
BloatingCholecystectomyDisorders of Gut-Brain InteractionUrgency

More Related Videos

Electroacupuncture Combined with Chinese Medicine Ironing Therapy for Functional Constipation
04:04

Electroacupuncture Combined with Chinese Medicine Ironing Therapy for Functional Constipation

Published on: July 5, 2024

1.2K
Postoperative Ileus Murine Model
04:26

Postoperative Ileus Murine Model

Published on: July 12, 2024

1.6K

Related Experiment Videos

Last Updated: Mar 28, 2026

Functional Assessment of Intestinal Motility and Gut Wall Inflammation in Rodents: Analyses in a Standardized Model of Intestinal Manipulation
09:44

Functional Assessment of Intestinal Motility and Gut Wall Inflammation in Rodents: Analyses in a Standardized Model of Intestinal Manipulation

Published on: September 11, 2012

23.1K
Electroacupuncture Combined with Chinese Medicine Ironing Therapy for Functional Constipation
04:04

Electroacupuncture Combined with Chinese Medicine Ironing Therapy for Functional Constipation

Published on: July 5, 2024

1.2K
Postoperative Ileus Murine Model
04:26

Postoperative Ileus Murine Model

Published on: July 12, 2024

1.6K

Area of Science:

  • Gastroenterology
  • Pharmacology
  • Clinical Trials

Background:

  • Irritable bowel syndrome with diarrhea (IBS-D) requires safe and effective treatments.
  • ORP-101 is a novel peripherally acting μ-opioid receptor agonist and κ-opioid receptor antagonist.
  • This study assessed ORP-101's efficacy and safety in IBS-D patients.

Purpose of the Study:

  • To evaluate the efficacy and safety of ORP-101 in patients with IBS-D.
  • To determine the optimal dosage of ORP-101 for IBS-D treatment.

Main Methods:

  • A randomized, double-blind, adaptive placebo-controlled trial was conducted.
  • Participants received ORP-101 (50 mg or 100 mg) or placebo daily for 12 weeks.
  • The primary endpoint was a composite response of abdominal pain and stool consistency.

Main Results:

  • 320 participants with IBS-D were randomized.
  • The 100 mg ORP-101 dose showed a response rate of 28.3% compared to 21.9% for placebo (p=0.12).
  • ORP-101 was well-tolerated, with no significant safety concerns, even in patients without gallbladders.

Conclusions:

  • ORP-101 100 mg did not reach statistical significance for the primary endpoint in this Phase II trial.
  • However, ORP-101 100 mg demonstrated positive trends across multiple key secondary endpoints.
  • Further research is warranted to explore ORP-101 for IBS-D and other chronic pain conditions.